Getting a new drug to market as fast — and as safely — as possible is a key focus for any researcher or developer manager at a pharmaceutical company, regardless of size.
In such a competitive environment, facing a delay of just a few months can give a rival company the chance to get to market first, so it is important that your drug moves through every step, from trials to approval, at top speed. However, in drug development, where drug failure rates have become a challenge, you have to not only account for speed, but also the thoroughness and quality of the data you use to make the right decisions at every stage of development.
“Anything that can shorten our timelines and reduce drug failure rates gives us a competitive advantage.” — Mark Collin, Medical Affairs Executive
In the earlier discovery stages, a researcher who is able to efficiently tap into current research and scientific trends in different therapeutic
